Clinical Trial Update: An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial [Phase 3]

View source ↗

Summary

An update on the RED-HF Phase 3 trial of darbepoetin alfa in heart failure shows an exploratory sub-study was conducted, and the trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cardiovascular Disease
• Heart Failure
• Ventricular Dysfunction

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)
• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Amgen | Conditions: Anemia, Cardiovascular Disease | Phase 3 | Status: TERMINATED